We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL

This study is currently recruiting participants.
Verified September 2017 by Robert Krause, MD, Medical University of Graz
Sponsor:
ClinicalTrials.gov Identifier:
NCT01576653
First Posted: April 12, 2012
Last Update Posted: September 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Robert Krause, MD, Medical University of Graz
  Purpose

In patients with invasive fungal infection (IFI) rapid diagnosis is essential for early initiation of appropriate antifungal therapy and thereby survival. Conventional culture is still the Gold-Standard for diagnosis of IFI. Sensitivity of conventional culture, however, is low (50%) and time to results minimum 24 hours.

Therefore usage of serological tests detecting fungal antigens has increased dramatically over recent years. Main advantages of this new methods are rapid results and higher sensitivity when compared to conventional culture. One of the most promising serological marker currently used is beta-D-Glucan, which is a component of the fungal cell wall. ß-D-Glucan has been detected in IFI caused by Aspergillus, Candida and Fusarium spp. The Fungitell Assay (Associates of Cape Code, Inc.) was developed and validated for detection of ß-D-Glucan in peripheral blood.

Up to date information about clinical performance of the Fungitell Assays in bronchoalveolar lavage fluid (BAL) is limited. This study will therefore evaluate clinical and diagnostic performance of the Fungitell Assay in BAL from patients with solid organ transplant or hematologic malignancy.

In addition Mn/A-Mn, the lateral flow device test for aspergillosis, and Galactomannan, as well as PCR will be determined and used as comparators for BDG performance.


Condition Intervention
Invasive Fungal Infection Hematological Malignancy Receipt of Solid Organ Transplant Other: Fungitell Assay in BAL

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Prospective Clinical Evaluation of Bata-D-Glucan Assay for Diagnosis of Invasive Fungal Infection in Blood and Bronchoalveolar Lavage

Resource links provided by NLM:


Further study details as provided by Robert Krause, MD, Medical University of Graz:

Primary Outcome Measures:
  • Fungitell Assay from BAL in patients with hematologic malignancy or ICU patients/patients after solid organ transplantation and suspected IFI [ Time Frame: 6 months after intervention ]
    Diagnostic potential of Fungitell Assay from BAL in patients with hematologic malignancy or ICU patients/ patients after solid organ transplantation and suspected IFI


Estimated Enrollment: 100
Study Start Date: June 2011
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: No IFI
Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
Other: Fungitell Assay in BAL
Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
Active Comparator: IFI
Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
Other: Fungitell Assay in BAL
Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • above 18 years of age
  • Bronchoscopy performed in clinical routine due to suspicion of IFI
  • Hematological malignancy or receipt of solid organ transplant/ICU

Exclusion Criteria:

  • below 18 years of age
  • No bronchoscopy performed
  • No Hematological malignancy nor receipt of solid organ transplant/ICU
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01576653


Contacts
Contact: Martin Hoenigl, MD +4331638581319 martin.hoenigl@medunigraz.at
Contact: Robert Krause, MD +4331638581796 robert.krause@medunigraz.at

Locations
Austria
Medical University of Graz Recruiting
Graz, Styria, Austria, 8036
Contact: Martin Hoenigl, MD       martin.hoenigl@medunigraz.at   
Principal Investigator: Martin Hoenigl, MD         
Sub-Investigator: Robert Krause, MD         
Sponsors and Collaborators
Robert Krause, MD
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Robert Krause, MD, MD, Medical University of Graz
ClinicalTrials.gov Identifier: NCT01576653     History of Changes
Other Study ID Numbers: 23-343
First Submitted: April 10, 2012
First Posted: April 12, 2012
Last Update Posted: September 22, 2017
Last Verified: September 2017

Keywords provided by Robert Krause, MD, Medical University of Graz:
IFI

Additional relevant MeSH terms:
Infection
Mycoses
Invasive Fungal Infections